AAV9-delivered AntagoNATs showed preclinical efficacy as a one-time treatment concept for Dravet syndrome, according to a report describing results in the context of SCN1A-driven disease. The approach targets the regulatory pathway behind gene expression control rather than replacing the gene via classic cDNA augmentation. Dravet syndrome is characterized by prolonged, often fever-triggered seizures beginning in infancy and is typically refractory to standard therapy. A one-time regimen, if it translates clinically, would represent a major operational and therapeutic shift for a lifelong condition. The excerpt does not include detailed outcome measures, but it frames the work as supporting a move beyond initial proof-of-concept for durability and seizure-related improvements. Preclinical durability across time points will likely be the decisive factor for investor and clinical attention in the next stage of development.